Thompson Davis & Co’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$352K Buy
+3,400
New +$303K 0.21% 93
2018
Q3
$79K Buy
+1,000
New +$71.5K 0.17% 136
2017
Q4
Sell
-92
Closed -$7K 769
2017
Q3
$7K Sell
92
-11
-11% -$870 0.01% 770
2017
Q2
$8K Sell
103
-13
-11% -$1.03K 0.01% 716
2017
Q1
$9K Sell
116
-473
-80% -$37.8K 0.01% 711
2016
Q4
$46K Sell
589
-1,852
-76% -$150K 0.08% 252
2016
Q3
$217K Sell
2,441
-165
-6% -$15.6K 0.38% 59
2016
Q2
$249K Buy
2,606
+14
+0.5% +$1.4K 0.4% 63
2016
Q1
$269K Sell
2,592
-83
-3% -$8.07K 0.4% 63
2015
Q4
$262K Sell
2,675
-405
-13% -$39.7K 0.37% 66
2015
Q3
$297K Buy
3,080
+63
+2% +$6.62K 0.42% 62
2015
Q2
$316K Sell
3,017
-56
-2% -$5.72K 0.36% 56
2015
Q1
$317K Sell
3,073
-464
-13% -$47K 0.38% 55
2014
Q4
$341K Sell
3,537
-269
-7% -$23.7K 0.39% 47
2014
Q3
$303K Buy
3,806
+1,272
+50% +$100K 0.39% 53
2014
Q2
$191K Buy
2,534
+1
+0% +$76 0.28% 93
2014
Q1
$190K Sell
2,533
-253
-9% -$17.9K 0.32% 78
2013
Q4
$199K Buy
+2,786
New +$179K 0.3% 78

Other funds holding CVS

Thompson Davis & Co's CVS Position: Q2 2026 in Review

Thompson Davis & Co opened a new position in CVS Health (CVS) in Q2 2026: 3,400 shares worth $352K. The stake represents 0.21% of the portfolio and ranks #93 among its holdings. This is a return to the name: Thompson Davis & Co previously reported a position in CVS as recently as Q3 2018.

Thompson Davis & Co first reported a position in CVS in Q4 2013 and has held it in 18 quarters since. 2,067 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • Thompson Davis & Co held 3,400 shares of CVS Health worth $352K as of Q2 2026.
  • CVS Health was a new Thompson Davis & Co position in Q2 2026.
  • CVS Health made up 0.21% of Thompson Davis & Co's portfolio in Q2 2026, its #93 holding.
  • Thompson Davis & Co first reported a position in CVS Health in Q4 2013 and has held it in 18 quarters since.
  • 2,067 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on Thompson Davis & Co's 13F filing for Q2 2026, filed 29 Jul 2026.